Definition for Code SystemProteinModificationTypeExample

{
  "resourceType" : "CodeSystem",
  "id" : "protein-modification-type",
  "meta" : {
    "lastUpdated" : "2026-07-04T18:53:58.933+00:00"
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem protein-modification-type</b></p><a name=\"protein-modification-type\"> </a><a name=\"hcprotein-modification-type\"> </a><p>This case-sensitive code system <code>http://hl7.org/fhir/protein-modification-type</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">PEGylated<a name=\"protein-modification-type-PEGylated\"> </a></td><td>PEGylated</td><td>Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol.</td></tr><tr><td style=\"white-space:nowrap\">lipidated<a name=\"protein-modification-type-lipidated\"> </a></td><td>Lipidated</td><td>Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec.</td></tr><tr><td style=\"white-space:nowrap\">Fc-fused<a name=\"protein-modification-type-Fc-fused\"> </a></td><td>Fc fusion</td><td>Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide.</td></tr><tr><td style=\"white-space:nowrap\">albumin-fused<a name=\"protein-modification-type-albumin-fused\"> </a></td><td>Albumin fusion</td><td>Fused to human serum albumin for half-life extension. Example: albiglutide.</td></tr><tr><td style=\"white-space:nowrap\">drug-conjugated<a name=\"protein-modification-type-drug-conjugated\"> </a></td><td>Drug-conjugated (ADC)</td><td>Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin.</td></tr><tr><td style=\"white-space:nowrap\">polysaccharide-conjugated<a name=\"protein-modification-type-polysaccharide-conjugated\"> </a></td><td>Polysaccharide-conjugated</td><td>Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines.</td></tr><tr><td style=\"white-space:nowrap\">glycoengineered<a name=\"protein-modification-type-glycoengineered\"> </a></td><td>Glycoengineered</td><td>Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC).</td></tr><tr><td style=\"white-space:nowrap\">amino-acid-substituted<a name=\"protein-modification-type-amino-acid-substituted\"> </a></td><td>Amino acid substituted</td><td>Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine.</td></tr><tr><td style=\"white-space:nowrap\">truncated<a name=\"protein-modification-type-truncated\"> </a></td><td>Truncated</td><td>Sequence is shortened relative to the parent protein.</td></tr><tr><td style=\"white-space:nowrap\">biotinylated<a name=\"protein-modification-type-biotinylated\"> </a></td><td>Biotinylated</td><td>Covalently labelled with biotin. Typical for research or diagnostic reagents.</td></tr><tr><td style=\"white-space:nowrap\">fluorescent-labeled<a name=\"protein-modification-type-fluorescent-labeled\"> </a></td><td>Fluorescent labelled</td><td>Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents.</td></tr></table></div>"
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
    "valueCode" : "brr"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
    "valueCode" : "informative"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
    "valueInteger" : 1
  }],
  "url" : "http://hl7.org/fhir/protein-modification-type",
  "version" : "6.0.0-ballot4",
  "name" : "ProteinModificationTypeExample",
  "title" : "Protein Modification Type",
  "status" : "active",
  "experimental" : true,
  "date" : "2026-06-30",
  "publisher" : "HL7 (FHIR Project)",
  "contact" : [{
    "telecom" : [{
      "system" : "url",
      "value" : "http://hl7.org/fhir"
    },
    {
      "system" : "email",
      "value" : "fhir@lists.hl7.org"
    }]
  }],
  "description" : "A high-level summary of how a protein has been modified, e.g. PEGylation, lipidation, Fc fusion. Useful for categorising modified biologics without enumerating the detailed chemistry.",
  "jurisdiction" : [{
    "coding" : [{
      "system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
      "code" : "001",
      "display" : "World"
    }]
  }],
  "caseSensitive" : true,
  "valueSet" : "http://hl7.org/fhir/ValueSet/protein-modification-type",
  "content" : "complete",
  "concept" : [{
    "code" : "PEGylated",
    "display" : "PEGylated",
    "definition" : "Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol."
  },
  {
    "code" : "lipidated",
    "display" : "Lipidated",
    "definition" : "Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec."
  },
  {
    "code" : "Fc-fused",
    "display" : "Fc fusion",
    "definition" : "Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide."
  },
  {
    "code" : "albumin-fused",
    "display" : "Albumin fusion",
    "definition" : "Fused to human serum albumin for half-life extension. Example: albiglutide."
  },
  {
    "code" : "drug-conjugated",
    "display" : "Drug-conjugated (ADC)",
    "definition" : "Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin."
  },
  {
    "code" : "polysaccharide-conjugated",
    "display" : "Polysaccharide-conjugated",
    "definition" : "Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines."
  },
  {
    "code" : "glycoengineered",
    "display" : "Glycoengineered",
    "definition" : "Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC)."
  },
  {
    "code" : "amino-acid-substituted",
    "display" : "Amino acid substituted",
    "definition" : "Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine."
  },
  {
    "code" : "truncated",
    "display" : "Truncated",
    "definition" : "Sequence is shortened relative to the parent protein."
  },
  {
    "code" : "biotinylated",
    "display" : "Biotinylated",
    "definition" : "Covalently labelled with biotin. Typical for research or diagnostic reagents."
  },
  {
    "code" : "fluorescent-labeled",
    "display" : "Fluorescent labelled",
    "definition" : "Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents."
  }]
}